Comparative Pharmacology
Head-to-head clinical analysis: ILOSONE SULFA versus SULFONAMIDES DUPLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOSONE SULFA versus SULFONAMIDES DUPLEX.
ILOSONE SULFA vs SULFONAMIDES DUPLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ilosone (erythromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Sulfa (sulfisoxazole) is a sulfonamide that inhibits dihydropteroate synthase, blocking folate synthesis. The combination provides synergistic bacteriostatic activity.
Sulfonamides are competitive antagonists of para-aminobenzoic acid (PABA) and inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
Each 5 mL suspension contains 250 mg erythromycin base and 600 mg sulfisoxazole; typical adult dose is 10 mL (2 tsp) every 6 hours, not to exceed 40 mL/day.
Oral: 500-1000 mg twice daily; maximum 2000 mg/day.
None Documented
None Documented
Erythromycin: 1.5-2 hours; Sulfisoxazole: 4-7 hours; clinical context: dose adjustment in renal impairment (CrCl <50 mL/min) needed for sulfisoxazole
Terminal half-life: 7-12 hours in patients with normal renal function; prolonged to 24-50 hours in renal impairment (CrCl <30 mL/min) due to reduced elimination.
Renal: 70-80% as unchanged drug and active metabolite (sulfisoxazole); Biliary: 10-15% as metabolites; Fecal: <5%
Renal: 70-100% unchanged drug via glomerular filtration and tubular secretion; fecal/biliary: <5%.
Category C
Category C
Macrolide and Sulfonamide Antibiotic
Sulfonamide Antibiotic